3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Urinary Bladder Neoplasms
3
Upper Tract Urothelial Carcinomas
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Lung Neoplasms
1
Acrocephalosyndactylia
1
Interventions
pemigatinib
2
pembrolizumab
1
infigratinib
1
erdafitinib
1
derazantinib
1
atezolizumab
1
Rogaratinib
1
Gemcitabine
1
Drug Combinations
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Acrocephalosyndactylia
×
infigratinib
×
Genitourinary
×
Clear all
NCT04972253
2022-08-10
(BLASST)-3
Dana-Farber Cancer Institute
Phase 1
Withdrawn